1) Geyer CE, et al : Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355 (26) : pp.2733-2743, 2006
2) Dahabreh IJ, et al : Trastuzumab in the adjuvant treatment of early耀tage breast cancer : a systematic review and meta analysis of randomized controlled trials. Oncologist, 13 (6) : pp.620-630, 2008
3) Liu X, et al : Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti葉umor effects of trastuzumab. Cancer Biol Ther, 5 (6) : pp.648-656, 2006
4) Crown JP, et al : Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat, 112 (2) : pp.317-325, 2008
5) Moy B, et al : Lapatinib預ssociated toxicity and practical management recommendations. Oncologist. 12 (7) : pp.756-765, 2007